VAROGLUTAMSTAT (PQ912, SIM0408)

Retrieved on:

Saturday, March 5, 2022

Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibrosis, Center for Drug Evaluation and Research, Patient, Clinical trial, CDE, NMPA, MOA, AD, Risk, Food, Antibody, Biotechnology, Safety, News, Inflammation, FDA, Therapy, Euronext Amsterdam, Plaque, HKEX, Fast Track, Company, Cancer, QPCT, Alzheimer's disease, Center, Medicine, Trial of the century, Judgement, National Medical Products Administration, Autoimmune disease, CCL2, Protein, Neuroinflammation, Brain, Partnership, Management, Pathology, Pharmaceutical industry, Medical imaging, Risk management, EU, Amyloid beta, Simcere Pharmaceutical, Varoglutamstat (PQ912, SIM0408), Vivoryon Therapeutics N.V., Simcere Pharmaceutical Group, VAROGLUTAMSTAT (PQ912, SIM0408), VIVORYON THERAPEUTICS N.V., SIMCERE PHARMACEUTICAL GROUP

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease (news with additional features)

Key Points:

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease (news with additional features)
The issuer is solely responsible for the content of this announcement.
"We are proud to have obtained CDE approval of our Clinical Trial Application of varoglutamstat which represents our strong commitment in the battle against Alzheimer's disease," said Dr. Renhong Tang, Executive Vice President of Simcere.
Varoglutamstat is currently in Phase 2 clinical development in Europe (VIVIAD study) and the U.S. (VIVA-MIND study).
Simcere focuses on oncology, central nervous system disease and autoimmune disease therapeutic areas, with a diversified product portfolio and industry-leading capabilities.